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Intraductal papilliary mucinous neoplasms (IPMNs), cystic lesions of the pancreas some of which are precursors of cancer, are increasingly diagnosed due to the increasing use of cross-sectional imaging (1) . According to the most recent WHO classification of Tumors of the Digestive System, IPMNs can be classified into four distinct histological subtypes: intestinal, gastric, pancreatobiliary (PB), and oncocytic, based on morphology of the papillae, cell differentiation pattern, and IHC staining for Mucin glycoproteins (MUCs) as well as Caudal Type Homeobox 2 (CDX2) (2) . The gastric type IPMN is characterized by small papillary structures and often contains areas with a flat mucinous epithelium. The mucinous cells are tall, with basally oriented nuclei similar to the foveolar epithelium of the stomach mucosa. These cells usually stain positive for MUC5AC and MUC6. Whereas the gastric papillae are small, the intestinal type IPMN contains long, villous papillae, and the epithelium is similar to the intestinal epithelium of the bowel with cells containing elongated, pseudostratified nuclei, and often goblets cells are present. The epithelium stains positive for MUC2 and CDX2 (a MUC2 regulating transcription factor) (3) and to a lesser extend for MUC5AC. The pancreaticobiliary type IPMN characteristically contains thin papillary structures with high grade dysplasia. The cells usually contain a more eosinophilic cytoplasm and more pleomorphic nuclei. These cells stain positive for MUC1, MUC5AC, and MUC6. Oncocytic IPMN is different from the other subtypes due to the severe complexity of the papillary structures and the distinct features of the epithelium. The cells of the oncocytic type are large, with an abundant eosinophilic granular cytoplasm. The cells stain positive for MUC6 but usually also for MUC5AC and focally MUC1 (2, 4) . Different subtypes have been described to have different prognosis, with the PB type having the worst outcome (5, 6) , whereas the gastric type IPMN is only seldom associated with high grade dysplasia (7) . The clinical importance of IPMN subtyping has recently been mentioned in the latest International consensus guidelines on diagnosis and treatment of IPMNs (4). The authors conclude cautiously, that subtyping as a part of the diagnostic workup of pancreatic cystic lesions could possibly be used for further risk stratification of the lesions (i.e. close surveillance instead of surgery could potentially be used in gastric type IPMNs). Currently, there is however no firm data on this issue. Aim of this article is to discuss pitfalls of MUC1 immunohistochemistry (IHC).
MATERIALS AND METHODS
Microbiopsy specimens were obtained from the wall of pancreatic cystic lesions by a novel endoscopic ultrasound (EUS)-guided through-the-needle-biopsy procedure. Microbiopsies from 18 patients and representative sections from surgical specimens (gastric, intestinal, and PB subtype as well as normal pancreatic tissue) were analyzed by IHC staining of different MUCs and CDX2. Antibodies used were: MUC1 (clone E29, dilution 1:50, Dako, Glostrup, Denmark); MUC2 (clone CCP58, undiluted, Dako, Glostrup, Denmark); MUC5AC (clone 45M1, dilution 1:500, Neomarkers, Portsmouth, USA); CDX2 (clone EPR2764Y, undiluted, Roche, Basel, Switzerland). Stainings were done on an automated platform (Ventana Benchmark Ultra). Two blinded senior pathologists (A.T. and J.P.H) specialized in pancreatic cancer scored the specimens independently. When the evaluation differed, a final decision was made by consensus. The results were evaluated based on the percentage of positively stained cells in case of MUC1, grade of dysplasia, morphological subtype of IPMNs, and an overall diagnosis of a IPMN subtype. Statistical analysis was performed by IBM SPSS Statistics version 25 (IBM Corp, Armonk, New York, USA) and a p-value of 0.05 was considered statistically significant. Interrater reliability was assessed by using intraclass correlation coefficient in case of percentage of positively stained cells and Cohen's kappa for all other evaluations.
The study was approved by the regional Ethics Committee (January 2nd, 2018, journal file number H-17031060).
RESULTS AND DISCUSSION

MUC1
When profiling IPMNs immunohistochemically, MUC1 is a key marker. According to the current WHO classification, it is strongly expressed in the PB subtype and absent or focally expressed in the other subtypes. MUC1 is a highly glycosylated protein, which can be modified in tumor cells. In pancreatic cancer, the malignant form of MUC1 is aberrantly glycosylated due to premature termination of the sugar chain elongation by sialylation (8, 9) . Thus, cancer-associated MUC1 is hypo-glycosylated. This enables IHC detection of the MUC1 core protein usually covered by full length sugar chains in the normal pancreas (10) . Intracellular uptake of hypo-glycosylated MUC1 is also increased without enhanced degradation and, due to loss of polarity in cancer cells, the protein is distributed all over the surface of tumor cells in sharp contrast with the normal epithelial cells, where MUC1 is confined to the apical surface (11) . Thus, immunohistochemically, presentation of MUC1 in pancreatic cancer cells is both cytoplasmic and membraneous.
Several antibodies have been developed to distinguish between the normal and malignant form of MUC1. Table 1 summarizes the most commonly used antibodies. Notably, antibodies used in the studies which laid ground for WHO's on classification of IPMNs all have specificity against either core MUC1 or sialylated MUC1, i.e. against the cancer-associated MUC1.
We have recently published a pilot study on EUS guided through-the-needle procurement of microbiopsy IPMN specimens, where we furthermore attempted subtyping according to the WHO classification (12) . We utilized a MUC1 antibody, E29, which has been validated as highly suitable for diagnostic use. E29 is raised using a preparation of milk fat globule membranes and thus, recognizes fully glycosylated MUC1 (13) . In contrast with the WHO classification, we observed a strong MUC1 staining, both cytoplasmic and membraneous, in gastric type IPMNs, and even in one specimen of intestinal type IPMN (Fig. 1C,D, Table 2 ). The inter-observer analysis showed complete agreement for positive staining of cells (j = 1.0, p < 0.0001). In all cases except one, MUC1 staining was positive in all cells (the remaining case was scored 80 and 90% positive cells respectively). In resected IPMN specimens, gastric, intestinal, and PB types were positive for MUC1 (Fig. 2F-H) . Normal pancreas was also MUC1 positive, albeit the staining was weaker and in concordance with the literature (14) (Fig. 1E) . Our laboratory is participating in the NordiQC quality control program (http://www. nordiqc.org), and MUC1 staining performance has been validated as optimal in the most recent assessment. In addition, interobserver-analysis showed complete agreement (j = 1.0, p < 0.0001) for positive staining of cells for MUC2, MUC5AC, and CDX2.
Our results clearly demonstrate the need for specification of usage of anti-MUC1 antibodies for subtyping of IPMNs. Microbiopsy specimens are small (1-2 mm), and usually contain few epithelial cells. Even though tissue architecture is observed in contrast with cytology, epithelial cells are scarce and, in our experience, papillary or villous structures are not observed. Absence of these histological features necessitates the use of MUC IHC in order to diagnose and successfully subtype IPMN lesions. However, according to the current WHO Classification, and based on MUC IHC, the gastric microbiopsy specimens from our study would be misclassified as PB, even though all lesions showed low-grade dysplasia. Recent articles and reviews quote the WHO classification or use identical anti-tumor MUC1 antibodies with no reflection on this (15) (16) (17) (18) . Analyzing the five studies quoted in the WHO classification, three use an antibody with specificity against MUC1 core (DF3 or Ma552) (19) (20) (21) anti-MUC1 core antibodies) included only gastric type and intestinal type IPMNs, and found both subtypes to be MUC1 negative (19, 23 (22) . Surgical specimens were used in all references. An overview of the commonly used antibodies can be seen in Table 1 .
Thorough comparison studies between the different MUC1 antibodies have been published by the authors behind the WHO classification references. Yonezawa et al. elegantly showed that when using MUC1 antibodies against core MUC1, most of the gastric type IPMNs were negative but when using antibodies against sialylated or fully glycosylated MUC1, the proportion of positive cases increases to 41% and 69% respectively (24). Horinouchi et al. came to the same conclusions, by investigating PB IPMNs (25) . Beatty et al. reported that the majority of MUC1 expression in IPMN was associated high-grade dysplasia is the under-glycosylated form, which is absent in the adjacent normal epithelium (26) . The findings support a recent report, where expression of a cancer-associated hypo-glycosylated MUC1 form in IPMN was found, and in some patients, cancer-associated MUC1 antibodies were detected (26) . Since there is no firm evidence in the literature on usage of MUC IHC for subtyping of IPMNs, and there is overlap of MUC protein expression in the different subtypes, we believe that additional prognostic markers should be employed.
Summarized, to reproduce staining patterns published in the WHO classification, an anti-core MUC1 antibody must be used. Antibodies against the fully glycosylated MUC1 will only reveal increased expression of MUC1 characteristic of the beginning of abnormality, whereas antibodies against the core region have an opportunity to show advancing IPMN lesions and to distinguish between different types. Considering that, we propose that the above mentioned MUC1 antibody heterogeneity should be emphasized in the next edition of the WHO classification, and that a more cautious recommendation about the use of mucin expression in the determination of IPMN subtype with specimens of limited cellularity may be employed.
